The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men

Table 4

Adverse events.

Study		General (𝑁 (%))					Specific (𝑁 (%))
		Any AE	Any serious AE	Death	Withdrawals due to AE
Alendronate							Placebo	Alendronate
Orwollet al.; [27]	Placebo		22 (23)		10 (11)	Any upper GI AE	21 (22)	37 (25)
	Alendronate		27 (18)		4 (3)	Dyspepsia	1 (1)	9 (6)
						Abdominal pain	4 (4)	12 (8)
						Esophagitis	1 (1)	1 (1)
						Reflux	5 (5)	7 (5)
Gonnelli et al.; [28]	Placebo; Alendronate			NA			NA
Risedronate							Placebo	Risedronate
Boonen et al.; [29]	Placebo (𝑛=93)	68 (73)	15 (16)	3 (3)	9 (9.7)	Any upper GI AE	17 (18)	16 (8)
						Constipation	5 (5)	16 (8)
	Risedronate (𝑛=191)	134 (70)	29 (15)	2 (1)	7 (3.7)	Back pain	2 (2)	13 (7)
						Arthralgia	8 (9)	11 (6)
						Influenza	5 (5)	11 (6)
						Nasopharyngitis	5 (5)	11 (6)
						Headache	0 (0)	10 (5)
Ibandronate							Placebo	Ibandronate
Orwoll et al.; [30]	Placebo	4 (9)	(7)	2		Any	4 (9)	16 (19)
	Ibandronate	16 (19)	(9)	1		Abdominal pain	(0)	(3)
Miacakcic
Owroll et al.; [30]	Placebo; Miacalcic	Very well tolerated and no significant side effects		0	0		NA
Teriparatide							Placebo	Teriparatide	Teriparatide
Trovas et al.; [31]	Placebo	39 patients	3	0	7	Nausea; Headache	3.4; NA	5.3; N A	18.7; 10. 8
	Teriparatide 20 μg	withdrew due to	3	2	14
	Teriparatide 40 μg	side-effects	0	0	18
Orwoll et al.; [32]	Teriparatide		0	0	0	Hypercalcemia	0	2
	Placebo		0	0	0	Redness at inj. site	0	5